(Q44108845)

English

The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations

scientific article published in July 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

based on heuristic

inferred from title

author name string

Alain Lafeuillade

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Gilles Hittinger

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Stéphane Chadapaud

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Serge Maillefet

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Alain Rieu

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Cécile Poggi

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

263-271

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Resistance against reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Direct analysis of mitochondrial toxicity of antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

1 reference

https://api.crossref.org/works/10.1310%2FX6B5-9K42-E25N-F680

21 January 2018

Identifiers

10.1310/X6B5-9K42-E25N-F680

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44108845&oldid=2106672190"